美国 · SEC FORM 4
MADRIGAL PHARMACEUTICALS, INC.
MDGL · Nasdaq · CIK 0001157601 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
57 同一窗口内观察到的 Form 4 交易行
49 sales · 8 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-08-20 · 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP · $23.1M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出High
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Sibold William JohnPresident and CEO
○▼▼▼
Levy Richard SDirector
▼○
Soergel DavidChief Medical Officer
▼▼
Taub RebeccaDirector
○
FOUSE JACQUALYN ADirector
○
Daly James MDirector
○
● 买入▼ 卖出○ 其他
Showing the six most active owners; 4 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-08-20 · 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP.
近期 Form 4 活动
0买入
202卖出
30其他 Form 4 交易行
39SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出49 sale line(s) · 仅供背景
其他8 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 2,396,369
- 上期报告
- 2,254,423
- 日均成交量
- 245,001
- 回补天数
- 9.8
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-08-20 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 59,901 | USD 385.16 | USD 23,071,405 | SEC 申报 ↗ |
| 2025-08-18 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 37,164 | USD 373.21 | USD 13,869,821 | SEC 申报 ↗ |
| 2025-08-18 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 68,618 | USD 364.04 | USD 24,979,848 | SEC 申报 ↗ |
| 2023-12-14 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 20,633 | USD 228.32 | USD 4,710,910 | SEC 申报 ↗ |
| 2023-12-13 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 81,159 | USD 219.39 | USD 17,805,862 | SEC 申报 ↗ |
| 2023-12-12 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 34,578 | USD 218.31 | USD 7,548,577 | SEC 申报 ↗ |
| 2023-11-21 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 64,350 | USD 188.47 | USD 12,128,192 | SEC 申报 ↗ |
| 2023-11-20 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 20,709 | USD 185.75 | USD 3,846,622 | SEC 申报 ↗ |
| 2023-11-17 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 46,370 | USD 174.70 | USD 8,100,636 | SEC 申报 ↗ |
| 2023-11-15 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 15,199 | USD 161.97 | USD 2,461,782 | SEC 申报 ↗ |
| 2023-11-14 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 34,188 | USD 156.42 | USD 5,347,687 | SEC 申报 ↗ |
| 2023-11-14 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 37,660 | USD 154.00 | USD 5,799,623 | SEC 申报 ↗ |
| 2023-11-13 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 买入 (P) | Common Stock | 69,839 | USD 143.21 | USD 10,001,444 | SEC 申报 ↗ |
Form 4 申报证据
232 transaction lines in the latest 365-day window; 889 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Sibold William John | 卖出 (S) | Common Stock | 5,221 | USD 542.38 | USD 2,831,792 | SEC 申报 ↗ |
| 2026-09-09 | Sibold William John | 卖出 (S) | Common Stock | 6,362 | USD 535.59 | USD 3,407,392 | SEC 申报 ↗ |
| 2026-08-17 | Kelley Shannon T | 卖出 (S) | Common Stock | 664 | USD 514.97 | USD 341,940 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Sibold William John | 卖出 (S) | Common Stock | 5,221 | USD 542.38 | USD 2,831,792 | SEC 申报 ↗ |
| 2026-09-09 | Sibold William John | 卖出 (S) | Common Stock | 6,362 | USD 535.59 | USD 3,407,392 | SEC 申报 ↗ |
| 2026-08-17 | Kelley Shannon T | 卖出 (S) | Common Stock | 664 | USD 514.97 | USD 341,940 | SEC 申报 ↗ |
| 2026-08-15 | REED JOHN C | 奖励／授予 (A) | Common Stock | 647 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-20 | Sibold William John | 卖出 (S) | Common Stock | 2,500 | USD 547.30 | USD 1,368,253 | SEC 申报 ↗ |
| 2026-07-17 | Sibold William John | 期权行权／转换 (M) | Common Stock | 50,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-17 | Taub Rebecca | 奖励／授予 (A) | Common Stock | 454 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | Levy Richard S | 奖励／授予 (A) | Common Stock | 454 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | FOUSE JACQUALYN A | 奖励／授予 (A) | Common Stock | 454 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | Daly James M | 奖励／授予 (A) | Common Stock | 454 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | Brennan Daniel J. | 奖励／授予 (A) | Common Stock | 404 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP | 奖励／授予 (A) | Common Stock | 908 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-01 | Soergel David | 卖出 (S) | Common Stock | 1,042 | USD 495.74 | USD 516,561 | SEC 申报 ↗ |
| 2026-05-22 | Levy Richard S | 卖出 (S) | Common Stock | 5,682 | USD 515.44 | USD 2,928,718 | SEC 申报 ↗ |
| 2026-05-18 | Soergel David | 卖出 (S) | Common Stock | 844 | USD 515.90 | USD 435,420 | SEC 申报 ↗ |
| 2026-03-06 | Taub Rebecca | 卖出 (S) | Common Stock | 491 | USD 431.94 | USD 212,083 | SEC 申报 ↗ |
| 2026-03-06 | Sibold William John | 卖出 (S) | Common Stock | 1,663 | USD 431.94 | USD 718,316 | SEC 申报 ↗ |
| 2026-03-06 | Kelley Shannon T | 卖出 (S) | Common Stock | 360 | USD 431.94 | USD 155,498 | SEC 申报 ↗ |
| 2026-03-06 | Huntsman Carole | 卖出 (S) | Common Stock | 419 | USD 431.94 | USD 180,983 | SEC 申报 ↗ |
| 2026-03-06 | Dier Mardi | 卖出 (S) | Common Stock | 1,982 | USD 430.87 | USD 853,993 | SEC 申报 ↗ |
| 2026-03-04 | Soergel David | 奖励／授予 (A) | Common Stock | 4,374 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-04 | Sibold William John | 奖励／授予 (A) | Common Stock | 14,995 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-04 | Kelley Shannon T | 奖励／授予 (A) | Common Stock | 4,017 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-04 | Huntsman Carole | 奖励／授予 (A) | Common Stock | 3,989 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-04 | Dier Mardi | 奖励／授予 (A) | Common Stock | 5,215 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-02 | Dier Mardi | 卖出 (S) | Common Stock | 1,183 | USD 427.21 | USD 505,389 | SEC 申报 ↗ |
| 2026-02-23 | Levy Richard S | 期权行权／转换 (M) | Common Stock | 2,500 | USD 7.36 | USD 18,400 | SEC 申报 ↗ |
| 2026-01-26 | Taub Rebecca | 卖出 (S) | Common Stock | 647 | USD 492.42 | USD 318,596 | SEC 申报 ↗ |
| 2026-01-26 | Sibold William John | 卖出 (S) | Common Stock | 1,577 | USD 492.42 | USD 776,546 | SEC 申报 ↗ |
| 2026-01-26 | Levy Richard S | 期权行权／转换 (M) | Common Stock | 4,000 | USD 16.46 | USD 65,840 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | MDGL |
| CIK | 0001157601 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 889 transaction lines from 2020-05-27 to 2026-09-11 192 P purchase lines · 531 S sale lines · 166 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.